wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36892544-17A220B9-BA44-48B1-A4B7-BBB3D8ABA345
Q36892544-17A220B9-BA44-48B1-A4B7-BBB3D8ABA345
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36892544-17A220B9-BA44-48B1-A4B7-BBB3D8ABA345
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
P2860
Q36892544-17A220B9-BA44-48B1-A4B7-BBB3D8ABA345
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36892544-17A220B9-BA44-48B1-A4B7-BBB3D8ABA345
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4c5f8f582d7aa9e392a77024b8423777f5faef56
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.